17-beta-hydroxysteroid dehydrogenase deficiency genotyping
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency genotyping On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency genotyping |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency genotyping |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency genotyping |
|
17-beta-hydroxysteroid dehydrogenase deficiency genotyping in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency genotyping |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
|
Risk calculators and risk factors for 17-beta-hydroxysteroid dehydrogenase deficiency genotyping |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
- 17 beta hydroxysteroid dehydrogenase deficiency is a condition with genotypically male and phenotypically female characteristics. There has been no phenotype to genotype correlation.
Genotyping
- 17 beta hydroxysteroid dehydrogenase deficiency is a condition with genotypically male and phenotypically female characterstics. There has been no phenotype to genotype correlation.[1]
References
- ↑ George MM, New MI, Ten S, Sultan C, Bhangoo A (2010). "The clinical and molecular heterogeneity of 17βHSD-3 enzyme deficiency". Horm Res Paediatr. 74 (4): 229–40. doi:10.1159/000318004. PMID 20689261.